Vania F Prado

Title: Vania F Prado: Innovator in Cholinergic Dysfunction Research

Introduction

Vania F Prado is a prominent inventor based in Belo Horizonte, Brazil. She has made significant contributions to the field of neuroscience, particularly in understanding cholinergic dysfunction and its implications for cognitive enhancement and myasthenia treatment. Her innovative work has led to the development of a unique mouse model that aids in evaluating potential therapeutic compounds.

Latest Patents

Vania F Prado holds a patent titled "Mouse model of cholinergic dysfunction to evaluate cognitive enhancers and drugs that improve myasthenia." This patent describes recombinant non-human mammals with reduced or no expression of vesicular acetylcholine transporter protein (VAChT). These mammals exhibit impaired performance in object and social recognition, neuromuscular performance, and alterations in autonomic nervous system function compared to their wild-type counterparts. The patent also outlines methods for screening compounds for cholinergic activity and their potential in treating cholinergic neurotransmission disorders. Additionally, it provides details on isolated nerve cells and cell cultures useful for in vitro screening of candidate compounds.

Career Highlights

Throughout her career, Vania F Prado has worked with esteemed institutions such as Duke University and Universidade Federal De Minas Gerais. Her research has focused on the mechanisms underlying cholinergic neurotransmission and the development of innovative models for studying related disorders.

Collaborations

Vania has collaborated with notable researchers, including Marc G Caron and Marco A Prado. These collaborations have further enriched her research and contributed to advancements in the understanding of cholinergic dysfunction.

Conclusion

Vania F Prado's work exemplifies the intersection of innovation and neuroscience. Her contributions through her patent and collaborations have the potential to significantly impact the treatment of cognitive disorders and enhance our understanding of cholinergic systems.